Targeting regulated cell death (RCD) with small-molecule compounds in triple-negative breast cancer: a revisited perspective from molecular mechanisms to targeted …

M Liao, R Qin, W Huang, HP Zhu, F Peng… - Journal of Hematology & …, 2022 - Springer
Triple-negative breast cancer (TNBC) is a subtype of human breast cancer with one of the
worst prognoses, with no targeted therapeutic strategies currently available. Regulated cell …

Resistance to intervention: paclitaxel in breast cancer

VM Dan, RS Raveendran… - Mini Reviews in Medicinal …, 2021 - ingentaconnect.com
Breast cancer stands as the most prevalent cancer in women globally, and contributes to the
highest percentage of mortality due to cancer-related deaths in women. Paclitaxel (PTX) is …

DREAM on: cell cycle control in development and disease

H Walston, AN Iness, L Litovchick - Annual review of genetics, 2021 - annualreviews.org
Perfectly orchestrated periodic gene expression during cell cycle progression is essential for
maintaining genome integrity and ensuring that cell proliferation can be stopped by …

Valerian and valeric acid inhibit growth of breast cancer cells possibly by mediating epigenetic modifications

F Shi, Y Li, R Han, A Fu, R Wang, O Nusbaum, Q Qin… - Scientific Reports, 2021 - nature.com
Valerian root (Valeriana officinalis) is a popular and widely available herbal supplement
used to treat sleeping disorders and insomnia. The herb's ability to ameliorate sleep …

Targeting histone modifications in breast cancer: a precise weapon on the way

W Li, H Wu, S Sui, Q Wang, S Xu… - Frontiers in cell and …, 2021 - frontiersin.org
Histone modifications (HMs) contribute to maintaining genomic stability, transcription, DNA
repair, and modulating chromatin in cancer cells. Furthermore, HMs are dynamic and …

Targeting BCL-xL improves the efficacy of bromodomain and extra-terminal protein inhibitors in triple-negative breast cancer by eliciting the death of senescent cells

SS Gayle, JM Sahni, BM Webb, KL Weber-Bonk… - Journal of Biological …, 2019 - ASBMB
Inhibitors of bromodomain and extra-terminal proteins (BETi) suppress oncogenic gene
expression and have been shown to be efficacious in many in vitro and murine models of …

[HTML][HTML] The emerging role of BET inhibitors in breast cancer

A Andrikopoulou, M Liontos, K Koutsoukos… - The Breast, 2020 - Elsevier
Bromodomain and extraterminal domain (BET) proteins are epigenetic molecules that
regulate the expression of multiple genes involved in carcinogenesis. Breast cancer is an …

Targeting super-enhancers as a therapeutic strategy for cancer treatment

Y He, W Long, Q Liu - Frontiers in pharmacology, 2019 - frontiersin.org
Super-enhancers (SEs) refer to large clusters of enhancers that drive gene expressions.
Recent data has provided novel insights in elucidating the roles of SEs in many diseases …

Targeting bromodomain and extraterminal proteins in breast cancer

JM Sahni, RA Keri - Pharmacological research, 2018 - Elsevier
Breast cancer is a collection of distinct tumor subtypes that are driven by unique gene
expression profiles. These transcriptomes are controlled by various epigenetic marks that …

[HTML][HTML] Breaking boundaries: Pan BETi disrupt 3D chromatin structure, BD2-selective BETi are strictly epigenetic transcriptional regulators

LM Tsujikawa, OA Kharenko, SC Stotz… - Biomedicine & …, 2022 - Elsevier
Background Bromodomain and extraterminal proteins (BETs) are more than just epigenetic
regulators of transcription. Here we highlight a new role for the BET protein BRD4 in the …